Dry Powder Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

Dry Powder Inhaler Devices Market Dynamics:

One of the main drivers of the dry powder inhaler devices market is the rising prevalence of diabetes. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes affected roughly 537 million people of age between 20-79 years. By the year 2030, the overall number of diabetes is expected to reach 643 million, and by 2045, it will reach 783 million. Thus, dry powder inhaler are used to treat diabetes by using insulin powder. Therefore, rising diabetes cases increases the demand of dry powder inhaler devices, which drives the overall dry powder inhaler devices market forward over the forecast period from 2024 to 2030.

Moreover, another key factor which is responsible for the growth of dry powder inhaler devices market is the increasing prevalence of asthma. For instance, according to World Health Organization (WHO) published data in the year 2023, asthma affected 262 million people in 2019 worldwide. Further, dry powder inhaler devices are used to deliver asthma medication to the lungs, thus increasing prevalence of asthma increases the demand for dry powder inhaler devices, which leads to a surge in the dry powder inhaler devices market during the forecast period.

However, lack of awareness about dry powder inhaler devices and disadvantages associated with the devices, can hamper the global dry powder inhaler devices market growth.

Dry Powder Inhaler Devices Market Segment Analysis:

Dry Powder Inhaler Devices Market by Product Type (Disposable, Capsule and Blister), Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, Diabetes, and Others), Type (Single-Use and Multi-Use), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the by type segment of dry powder inhaler devices market, single use is expected to share a significant revenue in the year 2023. Single use dry powder inhalers devices are disposable, cost effective, minimize the risk of infections, offers a better approach to deliver medications than reusable ones and can assist a variety of needs. Thus, these benefits associated with the single use dry powder inhaler devices increases its demand, which leads to a surge in the dry powder inhaler devices overall market. However, increase in patents approvals associated with the dry powder inhaler devices also drives its market growth.

In February 2020, Hovione Technology, a Contract Development and Manufacturing Company, has reported that one of its big dosage dry powder inhaler (DPI) systems, the TwinMax DPI, has received patent approvals. TwinMax is a 2-puff disposable DPI that is developed for applications that need a high dosage administration to the lungs. It has a patent-pending architecture that allows it to deliver dosages up to 100 mg as medication alone or tailored particles.

Furthermore, such type of approvals and benefits associated with single-use dry powder inhaler devices, in the product type segment would result in the rising demand for dry powder inhaler devices which in turn would provide a conducive growth for the overall dry powder inhaler devices market during the forecast 2024 to 2030.

North America is expected to dominate the overall Dry Powder Inhaler Devices Market:

Among all the regions, North America is expected to dominate the global dry powder inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. Factors such as the rising prevalence of respiratory infection and surge in cystic fibrosis cases are expected to increase the demand of dry powder inhaler devices in the North American market.

Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per cystic fibrosis Canada’s 2020 annual data report from the Canadian Cystic Fibrosis Registry, had released that in 2020, there were 4,332 Canadians with CF, with 62 percent of them being adults. Further, dry powder inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for dry powder inhaler devices, which boost the dry powder inhaler devices overall market growth.

Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in dry powder inhaler devices market.

Dry Powder Inhaler Devices Market Key Players:

Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, OtsUnited Kingdoma Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Höfliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, and among others.

Recent Developmental Activities in the Dry Powder Inhaler Devices:

• In June 2022, Glenmark Pharmaceuticals Ltd, a research-driven global integrated pharmaceutical company, is one of the first to introduce a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) in United Kingdom under the brand name Tiogiva® for the treatment of chronic obstructive pulmonary disease (COPD).
• In May 2020, Iconovo, offers the development of inhalation products, has announced that the ICOcapTM dry powder inhaler, which is based on capsules, has received CE approval for use in clinical studies.

Key Takeaways from the Dry Powder Inhaler Devices Market Report Study

● Market size analysis for current dry powder inhaler devices market (2023), and market forecast for 6 years (2024 to 2030)
● Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint venture happened over last 3 years
● Key companies dominating the global dry powder inhaler devices
● Various opportunities are available for the other competitor in the dry powder inhaler devices market space.

● What are the top-performing segments in 2023? How these segments will perform in 2030.

● Which are the top-performing regions and countries in the current dry powder inhaler devices market scenario?
● Which are the regions and countries where companies should have concentrated on opportunities for dry powder inhaler devices market growth in the coming future?

Target Audience who can be benefited from this Dry Powder Inhaler Devices Market Report Study

● Dry powder inhaler devices providers
● Research organizations and consulting companies
● Dry powder inhaler devices-related organizations, associations, forums, and other alliances
● Government and corporate offices
● Start-up companies, venture capitalists, and private equity firms
● Distributors and traders dealing in dry powder inhaler devices
● Various end-users who want to know more about the dry powder inhaler devices market and latest technological developments in the dry powder inhaler devices

Frequently Asked Questions for Dry Powder Inhaler Devices:

1. What are Dry Powder Inhaler Devices?

A Dry-Powder Inhaler (DPI) is a device that uses dry powder to deliver medicine to the lungs. DPIs are often used to treat respiratory disorders such as asthma, bronchitis, emphysema, and COPD, but they have also been used to treat diabetes mellitus.

2. What is the market for Dry Powder Inhaler Devices?

The dry powder inhaler devices market was valued atUSD 13.93 billion in 2023, growing at a CAGR of 4.58% during the forecast period from 2024 to 2030 to reachUSD 18.62 billion by 2030.

3. What are the drivers for the Dry Powder Inhaler Devices market?

The dry powder inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of respiratory disorders, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.

4. Who are the key players operating in the Dry Powder Inhaler Devices market?

Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, OtsUnited Kingdoma Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Höfliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS and among others.

5. Which region has the highest share in Dry Powder Inhaler Devices Market?

North America is expected to dominate the global Dry powder inhaler devices market. Factors contributing to the growth of dry powder inhaler devices market in the North America region are rising prevalence of cystic fibrosis cases.


This product will be delivered within 2 business days.